This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2011 Feb;104(2):37.

Effects of medical therapies on retinopathy progression in type 2 diabetes

A Egan, M Byrne

PMID: 21465870

Editorial

Effects of medical therapies on retinopathy progression in type 2 diabetes

A Egan et al. Ir Med J. 2011 Feb.

. 2011 Feb;104(2):37.

Authors

A Egan, M Byrne

PMID: 21465870

No abstract available

PubMed Disclaimer

Similar articles

[Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
Ai M, Yoshida M. Ai M, et al. Nihon Rinsho. 2010 Nov;68 Suppl 9:285-90. Nihon Rinsho. 2010. PMID: 21661165 Clinical Trial. Japanese. No abstract available.
Fenofibrate and diabetic retinopathy.
Liew G, Gillies M, Wang JJ. Liew G, et al. Lancet. 2008 Mar 1;371(9614):721; author reply 722. doi: 10.1016/S0140-6736(08)60332-3. Lancet. 2008. PMID: 18313494 No abstract available.
Retinopathy progression in type 2 diabetes.
Baum SJ. Baum SJ. N Engl J Med. 2010 Nov 25;363(22):2172; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105808 No abstract available.
Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Wong TY, Simó R, Mitchell P. Wong TY, et al. Am J Ophthalmol. 2012 Jul;154(1):6-12. doi: 10.1016/j.ajo.2012.03.013. Am J Ophthalmol. 2012. PMID: 22709833 Review.
Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
Dodson PM. Dodson PM. Eye (Lond). 2009 May;23(5):997-1003. doi: 10.1038/eye.2008.428. Epub 2009 Jan 23. Eye (Lond). 2009. PMID: 19169236 Review.

See all similar articles

Cited by

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Scotland G, Tsehaye M, Styles C, Logue J, Sammons E, Zayed M, Emberson J, Wade R, Wallendszus K, Stevens W, Cretney R, Harding S, Leese G, Currie G, Armitage J, Preiss D; LENS Collaborative Group. Scotland G, et al. Diabet Med. 2025 Sep;42(9):e70098. doi: 10.1111/dme.70098. Epub 2025 Jul 3. Diabet Med. 2025. PMID: 40607724 Free PMC article. Clinical Trial.
The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy-Literature Review.
Bryl A, Mrugacz M, Falkowski M, Zorena K. Bryl A, et al. J Clin Med. 2022 May 13;11(10):2761. doi: 10.3390/jcm11102761. J Clin Med. 2022. PMID: 35628887 Free PMC article. Review.
Association between body fat variation rate and risk of diabetic nephropathy - a posthoc analysis based on ACCORD database.
Li S, Lin L, Chen X, Liu S, Gao M, Cheng X, Li C. Li S, et al. BMC Public Health. 2024 Oct 14;24(1):2805. doi: 10.1186/s12889-024-20317-y. BMC Public Health. 2024. PMID: 39396960 Free PMC article.
Early Worsening of Retinopathy in Type 1 and Type 2 Diabetes After Rapid Improvement in Glycaemic Control: A Systematic Review.
Akil H, Burgess J, Nevitt S, Harding SP, Alam U, Burgess P. Akil H, et al. Diabetes Ther. 2022 Jan;13(1):1-23. doi: 10.1007/s13300-021-01190-z. Epub 2021 Dec 20. Diabetes Ther. 2022. PMID: 34928488 Free PMC article. Review.
The Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy-A Review of the Literature.
Bryl A, Mrugacz M, Falkowski M, Zorena K. Bryl A, et al. Nutrients. 2022 Mar 16;14(6):1252. doi: 10.3390/nu14061252. Nutrients. 2022. PMID: 35334909 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information